Literature DB >> 30253192

Interaction of miR-125b-5p with Human antigen R mRNA: Mechanism of controlling HCV replication.

Shivaprasad Shwetha1, Geetika Sharma1, Harsha Raheja1, Amit Goel2, Rakesh Aggarwal2, Saumitra Das3.   

Abstract

Cellular miRNAs influence Hepatitis C virus (HCV) infection in multiple ways. In this study, we demonstrate that miR-125b-5p is upregulated in HCV infected patient serum samples as well as in HCV infected liver carcinoma cells and is involved in translational regulation of one of its predicted targets, Human antigen R (HuR). We used miRNA mimics and antagomiRs to confirm that HuR is a bonafide miR-125b target. Previously, we have shown that HuR is a positive regulator of HCV replication, whereas we noticed that miR-125b is a negative regulator of HCV infection. As a connecting link between these two observations, we showed that knockdown of miR-125b-5p increased HuR protein levels and rescued HCV replication when the availability of HuR in the cytoplasm was compromised using siRNAs against HuR or an inhibitor of HuR export to the cytoplasm. Overall, the study sheds light on the ability of host cell to use a miRNA as a tool to control virus propagation.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HCV; HuR; Translation; Viral replication; miR-125b-5p

Mesh:

Substances:

Year:  2018        PMID: 30253192     DOI: 10.1016/j.virusres.2018.09.006

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  8 in total

1.  Cellular Protein HuR Regulates the Switching of Genomic RNA Templates for Differential Functions during the Coxsackievirus B3 Life Cycle.

Authors:  Pratik Dave; Priya Rani; Biju George; Padmanava Behera; Saumitra Das
Journal:  J Virol       Date:  2021-08-18       Impact factor: 5.103

2.  A Major Downregulation of Circulating microRNAs in Zika Acutely Infected Patients: Potential Implications in Innate and Adaptive Immune Response Signaling Pathways.

Authors:  Ana Carolina Carvalho-Silva; Almir Ribeiro Da Silva Junior; Vagner Oliveira-Carvalho Rigaud; Waleska Kerllen Martins; Verônica Coelho; Irmtraut Araci Hoffmann Pfrimer; Jorge Kalil; Simone Gonçalves Fonseca; Edecio Cunha-Neto; Ludmila Rodrigues Pinto Ferreira
Journal:  Front Genet       Date:  2022-06-01       Impact factor: 4.772

3.  The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis.

Authors:  Serena Lorini; Laura Gragnani; Anna Linda Zignego
Journal:  Viruses       Date:  2020-11-29       Impact factor: 5.048

Review 4.  Overview of host miRNA properties and their association with epigenetics, long non-coding RNAs, and Xeno-infectious factors.

Authors:  Samaneh Heydarzadeh; Maryam Ranjbar; Farokh Karimi; Farhad Seif; Mohammad Reza Alivand
Journal:  Cell Biosci       Date:  2021-02-25       Impact factor: 7.133

Review 5.  MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes.

Authors:  Cyril Sobolewski; Laurent Dubuquoy; Noémie Legrand
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

Review 6.  Roles of microRNAs in Hepatitis C Virus Replication and Pathogenesis.

Authors:  Hui-Chun Li; Chee-Hing Yang; Shih-Yen Lo
Journal:  Viruses       Date:  2022-08-15       Impact factor: 5.818

7.  Mechanism of selenomethionine inhibiting of PDCoV replication in LLC-PK1 cells based on STAT3/miR-125b-5p-1/HK2 signaling.

Authors:  Zhihua Ren; Ting Ding; Hongyi He; Zhanyong Wei; Riyi Shi; Junliang Deng
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

8.  Integrated Regulation of HuR by Translation Repression and Protein Degradation Determines Pulsatile Expression of p53 Under DNA Damage.

Authors:  Abhishek Guha; Deepika Ahuja; Sukhen Das Mandal; Bibudha Parasar; Krishanu Deyasi; Debadrita Roy; Vasundhara Sharma; Belinda Willard; Anandamohan Ghosh; Partho Sarothi Ray
Journal:  iScience       Date:  2019-05-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.